AXL and neoplasm: TP‐0903, a novel oral Axl inhibitor, has demonstrated efficacy in restraining tumor cell proliferation, metastasis, and enhancing sensitivity to chemotherapeutic agents across various solid tumors and hematological malignancies.[236, 237, 238, 239] Cabozantinib, a multireceptor tyrosine kinase inhibitor, has shown promise in preclinical trials by modulating multiple signaling pathways to impede cancer cell growth, metastasis, and neovascularization.